Personalized Medicine, Breast Cancer, and the SPHA History
Breast cancer prevention, early detection, personalized care, and research exemplify the SPH Analytics story. In 2014, the year that SPH Analytics (SPHA) was founded (as Symphony Performance Health), Dr. Ron Ribitzky was the Principal Author and Chief Editor of the book “Knowledge Mining & Bioinformatics Techniques to Advance Personalized Diagnostics & Therapeutics: The Case for White Space R&D”. In this National Science Foundation’s sponsored publication, Dr. Ribitzky, Dr. Ron as he is known in the office, discusses value drivers which are the key reasons for taking action. These value drivers identify the key performance indicators (KPIs) that define successful outcomes. With the KPIs identified, it is possible to gather the data needed to analyze progress toward the desired action. Dr. Ron refers to this data as Value Measures:
In my view, early detection of Breast Cancer is a perfect example of the life-saving gift that keeps on giving by the tremendous complementary potential of economic and scientific value for all of us and for generations to come. I call it the ‘Perpetual Personalized Medicine Value Effect’.
Consider these Value Measures which would define what data we need to collect and analyze, and what actions we can and probably should take as a result:
- 50% of Family Physicians will use personalized medicine decision support for 50% of their patients in 5 years
- 20% of patients with breast cancer are cured in 2 years
- 30% reduction of cost of care of breast cancer patients in 5 years
- Translational cycle under 2 years in 5 years
- Anonymous comprehensive clinical data of 100 million people is available in 5 years; 10X growth of the number of patients in the following 5 years
SPH Analytics acquired MDinsight (MDI), our population health tool, to help providers and health plans engage with their patients and members in a continuous effort to prevent illness, promote wellness, and provide measurable quality care in a manner that creates value to all. With MDI, quality and value measures are set and actions are guided and managed. Breast cancer screening is an important KPI built into MDI’s Breast Cancer Clinical Suite. Dr. Ron says, “at SPH Analytics we provide a tool set that measures, analyzes, and enables taking action for the prevention and early detection of chronic diseases such as breast cancer, and provide proper care as may become necessary.”
Breast Cancer and Personalized Medicine–Our Commitment
Our efforts this month to bring awareness and education to our employees and their families, raise funds for breast cancer research and related causes, and support those in our office who are survivors of breast cancer exceeded everyone’s expectations.
We are committed to helping clinicians coordinate care for breast cancer patients and their families every day. We continue to expand the capabilities of MDI, extend its reach to provide personalized predictive health management through IndiGO, and collaborate with other vendors to embed these capabilities into their EMR and patient outreach solutions. And we are bringing patient experience, satisfaction, and service recovery tools into our next generation analytic platforms to allow care teams to spend more quality and valuable time with patients while efficiently monitoring progress on mandated care measures and economic performance to benefit patients, members, providers, and payers.
At SPH Analytics, bringing value and quality care is our KPI.